Picture: Evox Therapeutics

Evox Therapeutics appoints Chief Medical Officer

Oxford-based Evox Therapeutics appoints Sonya Montgomery in the newly formed position of Chief Medical Officer.

Montgomery has worked in the Life Sciences for almost 25 years. She joins the exosome therapeutics company Evox from Gyroscope Therapeutics. There, she held the position of Vice President, Head of Clinical Development. She played a key role in the company’s £50m Series B financing round and oversaw the company’s transition from biotech start-up to clinical stage company. Prior to this, she was VP Clinical Development at ProQR where she led the company’s cystic fibrosis business. In 2012, Montgomery worked at Relypsa as Executive Director Clinical Development and led a pivotal programme in the EU and US for patiromer (Veltassa) treating hyperkalaemia in chronic kidney disease and heart failure. And before that, she was a clinical lead at Pfizer.

Dr Antonin de Fougerolles, Chief Executive Officer of Evox, said: “We are very excited to have an executive of Sonya’s experience join our team as we advance our pioneering exosome-based therapeutics towards the clinic. A Chief Medical Officer with such extensive knowledge of translational science alongside clinical and regulatory experience in rare diseases will be invaluable as we look to deliver on the clinical potential in our pipeline. Sonya is an excellent addition to our leadership team and will play a central role in shaping Evox's clinical development strategy.”